Spots Global Cancer Trial Database for Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

Official Title: Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma

Study ID: NCT01065870

Conditions

Pancreatic Cancer Stage II

Pancreatic Cancer Stage III

Interventions

Neoadjuvant gemcitabine, capecitabine, and docetaxel

Gemcitabine, capecitabine, docetaxel followed by radiotherapy

Study Description

Brief Summary: This study is for patients with locally advanced pancreatic cancer (cancer that involves the local blood vessels so it cannot be removed without cutting major blood vessels) that cannot be treated with surgery. The purpose of this study is to assess the safety and benefit of 6 three week cycles of chemotherapy treatment consisting of gemcitabine, capecitabine and docetaxel (also called 'GTX'). The patients fall into two groups. Group I are those with only venous involvement. Group II patients have arterial involvement and may also have venous involvement. If there is arterial involvement, GTX will be followed by 5 and 1/2 weeks of radiation therapy with gemcitabine and capecitabine. After the chemotherapy and radiation treatment, participants may be able to have surgery to remove any remaining pancreatic cancer.

Detailed Description: